877-202-0205     support@chemchart.com     @chemchart
        
Sign In    Register
   Reset Filters

Alkaloids, Antineoplastic and immunomodulating drugs

Categories

Antineoplastic drugs (7)
Pharmaceuticals (5)
Antineoplastic and immunomodulating drug (4)
Alcohols (3)
DNA replication inhibitors (3)
Topoisomerase inhibitors (3)
Aromatase inhibitors (2)
Hormonal agents (2)
Hormonal antineoplastic drugs (2)
Ketones (2)
Systemic hormonal preparations (2)
Anti-inflammatory agents (1)
Anti-inflammatory and antirheumatic products (1)
Consumer Ingredients (1)
DNA-binding substances (1)
Drugs acting on the musculoskeletal system (1)
Drugs acting on the nervous system (1)
Experimental cancer drugs (1)
Melatonergic (1)
Melatonin (1)
Melatonin receptor agonists (1)
Mitotic inhibitors (1)
Musculoskeletal system drug (1)
Psychoactive drugs (1)
Quaternary ammonium compounds (1)
Quaternary compounds (1)
Tryptamine alkaloids (1)
Tryptamines (1)

Suppliers

Sigma Aldrich (5)
Matrix Scientific (2)
TCI Chemicals (2)
AK Scientific (1)
Amazon (1)
Apollo Scientific (1)
Frontier Scientific (1)
Oakwood Chemical (1)
Toronto Research Chemicals (1)

Melatonin (8041-44-9, 73-31-4)  
Melatonin, also known as N-acetyl-5-methoxy tryptamine, is a hormone that is produced by the pineal gland in animals and regulates sleep and wakefulness. Melatonin is also produced in plants where it functions as a first line of defense against oxidative stress. In animals, melatonin is involved in the entrainment (synchronization) of the circadian rhythms including sleep-wake timing, blood pressure regulation, seasonal reproduction, and many others.
camptothecin (7689-03-4)  
Camptothecin (CPT) is a topoisomerase inhibitor. It was discovered in 1966 by M. E.
swainsonine (72741-87-8)  
Swainsonine is an indolizidine alkaloid. It is a potent inhibitor of Golgi alpha-mannosidase II, an immunomodulator, and a potential chemotherapy drug. As a toxin in locoweed (likely its primary toxin) it also is a significant cause of economic losses in livestock industries, particularly in North America.
berberine (2086-83-1, 4263-84-7)  
Umbellatine
Berberine is a quaternary ammonium salt from the protoberberine group of benzylisoquinoline alkaloids found in such plants as Berberis (e.g. Berberis vulgaris - barberry, Berberis aristata - tree turmeric, Mahonia aquifolium - Oregon-grape, Hydrastis canadensis - goldenseal, Xanthorhiza simplicissima - yellowroot, Phellodendron amurense - Amur cork tree, Coptis chinensis - Chinese goldthread, Tinospora cordifolia, Argemone mexicana - prickly poppy, and Eschscholzia californica - Californian poppy. Berberine is usually found in the roots, rhizomes, stems, and bark.
Demecolcine (477-30-5)  
Colcemid  ·  Colcemide  ·  Colchamine
colcemid (477-30-5)  
Demecolcine  ·  Colcemide  ·  Colchamine
Demecolcine, also known as Colcemid, is a drug used in chemotherapy. It is closely related to the natural alkaloid colchicine with the replacement of the acetyl group on the amino moiety with methyl, but it is less toxic. It depolymerises microtubules and limits microtubule formation (inactivates spindle fibre formation), thus arresting cells in metaphase and allowing cell harvest and karyotyping to be performed.
CEPHARANTHINE (481-49-2)  
Cepharanthine is an antiinflammatory and antineoplastic compound isolated from Stephania. Due to these modalities, it has been shown effective against HTLV in lab research. Additionally, it has successfully been used to treat a diverse range of medical conditions, including radiation-induced leukopenia, idiopathic thrombocytopenic purpura, alopecia areata, alopecia pityrodes, venomous snakebites, xerostomia, sarcoidosis, refractory anemia and various cancer-related conditions.
Vinflunine (162652-95-1)  
Vinflunine (INN, trade name Javlor) is a novel fluorinated vinca alkaloid derivative undergoing research for the treatment of bladder cancer. It was originally discovered by the team of the Professor Jean-Claude Jacquesy (UMR CNRS 6514 - Poitiers University), developed by Laboratoires Pierre Fabre and was licensed to Bristol-Myers Squibb for development in certain countries, including the United States. On November 23, 2007, Pierre Fabre Medicament and Bristol-Myers Squibb announced that they were terminating their license agreement for the development of vinflunine, and that Pierre Fabre were continuing "discussions with regulatory authorities and plan to file for the registration of vinflunine for bladder cancer in the first quarter of 2008." As of 2016, vinflunine is the only commercially-approved agent in some countries for salvage therapy of urothelial carcinoma, (with approval based on the results of a phase III trial), with a reported median OS of about 6 months.
Related searches
Alkaloids
Antineoplastic and immunomodulating drugs